PSB-12062, >=98% (HPLC)

Not available outside of the UK & Ireland.

Application

PSB-12062 has been used as a P2X4 antagonist to pre-treat macrophages in inhibitor screening studies to understand the inflammation process. It has also been used as P2X4 antagonists to pre-treat P2X7-deficient BV-2 cells to elucidate the roles of P2X4.

Biochem/physiol Actions

PSB-12062 is a P2X4 receptor antagonist. P2X4 receptors are highly expressed in the central nervous system (CNS), and have been studied as a therapeutic target for neutopathic pain, and treatment of traumatic brain injury, cerebral ischemia, and spinal cord injury. PBS-12062 is a new P2X4-specific antagonist with equal potency against human, rat and mouse receptors (IC₅₀s 1.38, 0.92 and 1.76 µM, respecitively). The compound does not display significant inhibition of human P2X1, P2X2, P2X3 or P2X7 at 10 µM.

Packaging

5, 25 mg in glass bottle